3/20
06:39 pm
ctmx
CytomX Therapeutics (CTMX) was downgraded by
Weiss Ratings from "hold (c-)" to "sell (d)".
Low
Report
CytomX Therapeutics (CTMX) was downgraded by
Weiss Ratings from "hold (c-)" to "sell (d)".
3/19
10:44 am
ctmx
CytomX Therapeutics (CTMX) had its price target raised by Barclays PLC from $10.00 to $16.00. They now have an "overweight" rating on the stock.
Low
Report
CytomX Therapeutics (CTMX) had its price target raised by Barclays PLC from $10.00 to $16.00. They now have an "overweight" rating on the stock.
3/18
02:07 pm
ctmx
CytomX Therapeutics (CTMX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Medium
Report
CytomX Therapeutics (CTMX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/18
10:07 am
ctmx
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level [Seeking Alpha]
High
Report
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level [Seeking Alpha]
3/18
09:17 am
ctmx
CytomX Therapeutics (CTMX) had its price target raised by Guggenheim from $10.00 to $15.00. They now have a "buy" rating on the stock.
High
Report
CytomX Therapeutics (CTMX) had its price target raised by Guggenheim from $10.00 to $15.00. They now have a "buy" rating on the stock.
3/18
01:41 am
ctmx
CytomX Therapeutics prices $250M public offering at $5.30 per share [Seeking Alpha]
High
Report
CytomX Therapeutics prices $250M public offering at $5.30 per share [Seeking Alpha]
3/17
11:00 pm
ctmx
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
High
Report
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
3/17
10:46 pm
ctmx
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
High
Report
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
3/17
02:13 pm
ctmx
CytomX Therapeutics: Still Some Ways To Go [Seeking Alpha]
Medium
Report
CytomX Therapeutics: Still Some Ways To Go [Seeking Alpha]
3/17
08:43 am
ctmx
CytomX Therapeutics (CTMX) had its price target raised by Wedbush from $6.00 to $11.00. They now have an "outperform" rating on the stock.
High
Report
CytomX Therapeutics (CTMX) had its price target raised by Wedbush from $6.00 to $11.00. They now have an "outperform" rating on the stock.
3/16
07:27 pm
ctmx
CytomX Therapeutics, Inc. [CNN]
High
Report
CytomX Therapeutics, Inc. [CNN]
3/16
07:00 pm
ctmx
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data [Yahoo! Finance]
High
Report
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data [Yahoo! Finance]
3/16
04:33 pm
ctmx
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
High
Report
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
3/16
04:04 pm
ctmx
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
High
Report
CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
3/16
03:28 pm
ctmx
CytomX Therapeutics Inc (CTMX) Q4 2025 Earnings Call Highlights: Promising Phase 1 Data and ... [Yahoo! Finance]
Low
Report
CytomX Therapeutics Inc (CTMX) Q4 2025 Earnings Call Highlights: Promising Phase 1 Data and ... [Yahoo! Finance]
3/16
02:02 pm
ctmx
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade) [Seeking Alpha]
High
Report
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade) [Seeking Alpha]
3/16
12:39 pm
ctmx
CytomX surges on positive data for ‘masked' ADC in colorectal cancer [Yahoo! Finance]
High
Report
CytomX surges on positive data for ‘masked' ADC in colorectal cancer [Yahoo! Finance]
3/16
12:23 pm
ctmx
CytomX Therapeutics (CTMX) had its price target raised by HC Wainwright from $10.00 to $17.00. They now have a "buy" rating on the stock.
High
Report
CytomX Therapeutics (CTMX) had its price target raised by HC Wainwright from $10.00 to $17.00. They now have a "buy" rating on the stock.
3/16
12:08 pm
ctmx
CytomX Therapeutics (CTMX) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
High
Report
CytomX Therapeutics (CTMX) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
3/16
11:59 am
ctmx
CytomX Therapeutics (CTMX) was upgraded by JPMorgan Chase & Co. from "neutral" to "overweight". They now have a $12.00 price target on the stock, up from $7.00.
High
Report
CytomX Therapeutics (CTMX) was upgraded by JPMorgan Chase & Co. from "neutral" to "overweight". They now have a $12.00 price target on the stock, up from $7.00.
3/16
10:03 am
ctmx
CytomX Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
CytomX Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/16
07:30 am
ctmx
CytomX Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
CytomX Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
3/16
07:08 am
ctmx
CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer [Yahoo! Finance]
Medium
Report
CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer [Yahoo! Finance]
3/16
07:08 am
ctmx
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/16
07:05 am
ctmx
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update
Medium
Report
CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update